Get started
Author

Juan Solivera

Observed names: J Solivera, J. Solivera, Solivera, J., Solivera, Juan, Vela Juan Solivera
ORCID: 0000-0003-2860-6656
Observed ORCID: 0000-0003-2860-6656
OpenAlex ID: A5108128158
Metformin and simvastatin exert additive antitumour effects in glioblastoma via senescence-state: clinical and translational evidence
2023 · Antonio C. Fuentes-Fayos, Miguel E. G-García, et al. · EBioMedicine · 47
PDF
SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances
2022 · Antonio C. Fuentes-Fayos, Jesús M. Pérez-Gómez, et al. · Journal of Experimental & Clinical Cancer Research · 43
PDF
Nonhistological diagnosis of human cerebral tumors by 1H magnetic resonance spectroscopy and amino acid analysis.
2000 · J M Roda, J M Pascual, et al. · PubMed · 33
Integrative Clinical, Radiological, and Molecular Analysis for Predicting Remission and Recurrence of Cushing Disease
2022 · Paloma Moreno-Moreno, Alejandro Ibáñez-Costa, et al. · The Journal of Clinical Endocrinology & Metabolism · 8
PDF
Dose escalation with intraoperative radiotherapy in newly diagnosed glioblastoma (INTRAGO-II): an open-label, multicentre, randomised, controlled, phase 3 trial
2026 · Frank Anton Giordano, Oliver Ganslandt, et al. · The Lancet Oncology · 4
Impaired splicing machinery in craniopharyngiomas unveils PRPF8 and RAVER1 as novel biomarkers and therapeutic targets
2025 · Antonio C. Fuentes-Fayos, Miguel E. G-García, et al. · Acta Neuropathologica Communications · 2
PDF
Letter to the Editor. Methodology and interpretation of intraoperative neuromonitoring during intracranial aneurysm clipping
2021 · Dimitrios Kefalas, Gemma Pérez-Fajardo, et al. · Journal of neurosurgery · 1
PDF
P13.11 Metabolomics and molecular profiling in glioma patients: an interactomic approach
2019 · A C Fuentes-Fayos, M L Gandía-González, et al. · Neuro-Oncology · 1
P11.17 Splicing dysregulation drives glioblastoma malignancy: SRSF3 as a potential therapeutic target to impair glioblastoma progression
2019 · A C Fuentes-Fayos, M C Vázquez-Borrego, et al. · Neuro-Oncology · 1
Biguanides exert antitumoral actions in pituitary tumor cells through AMPK-dependent and -independent mechanisms
2019 · Aura D Herrera-Martinez, Mari C Vazquez-Borrego, et al. · Endocrine Abstracts · 1
The telomerase/shelterin system is impaired in acromegaly and Cushing´s disease: Potential pathophysiological relevance
2026 · Miguel E. G-García, Ana S. De la Rosa-Herencia, et al. · Biomedicine & Pharmacotherapy
Spliceosome approach for the identification of diagnostic and prognostic biomarkers and therapeutic targets in paediatric brain tumors
2025 · De la Rosa-Herencia Ana S., Juana Vidal-Minano, et al. · Endocrine Abstracts
Characterization of telomerase/shelterin system in endocrine intracranial tumors at clinical, transcriptomic, and functional levels
2023 · Miguel E. G-Garcia, Alvaro Flores-Martinez, et al. · Endocrine Abstracts
Figure S3 from A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023 · Mari C. Vázquez-Borrego, Vandana Gupta, et al.
Supplementary Data from A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023 · Mari C. Vázquez-Borrego, Vandana Gupta, et al.
PDF
Data from A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023 · Mari C. Vázquez-Borrego, Vandana Gupta, et al.
Figure S2 from A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023 · Mari C. Vázquez-Borrego, Vandana Gupta, et al.
Data from A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023 · Mari C. Vázquez-Borrego, Vandana Gupta, et al.
Figure S6 from A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023 · Mari C. Vázquez-Borrego, Vandana Gupta, et al.
PDF
Figure S5 from A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023 · Mari C. Vázquez-Borrego, Vandana Gupta, et al.
Figure S4 from A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023 · Mari C. Vázquez-Borrego, Vandana Gupta, et al.
Figure S5 from A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023 · Mari C. Vázquez-Borrego, Vandana Gupta, et al.
PDF
Figure S2 from A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023 · Mari C. Vázquez-Borrego, Vandana Gupta, et al.
PDF
Figure S3 from A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023 · Mari C. Vázquez-Borrego, Vandana Gupta, et al.
PDF
Figure S7 from A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023 · Mari C. Vázquez-Borrego, Vandana Gupta, et al.
Works count: 47
Citation count: 141
H-index: 4
I10-index: 3
Year
Topic
Type